Stockwatch: Dynavax, CoLucid Investors Should Beware The Standard Of Care
Dynavax and CoLucid benefited from share price surges last week. But were investors throwing caution to the wind and overlooking the challenges and lessons presented by standard of care therapies? Meanwhile, bluebird bio’s stock soared again.
Register for our free email digests: